ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40658684

Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response.

Qiu Y and 5 others. PLoS Biol, 2025. Cited by 23 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response. Papers, record 40658684. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40658684

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response.
PubMed
Journal
PLoS Biol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
6.01, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Qiu YYajing
2Xu YYihan
3Ding XXinyuan
4Zhao CCongcong
5Cheng HHongcheng
6Li GGuidenghttps://orcid.org/0000-0003-0840-7262

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
T-LymphocytesMajor topic
Animals
Humans
Cell Communication
Cellular Reprogramming
Metabolic Reprogramming
Tumor Microenvironment

Source PubMed

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Noncommunicable Chronic Diseases-National Science and Technology Major ProjectPubMed
National Natural Science Foundation of ChinaPubMed
Central Research Institute Fund of the Chinese Academy of Medical SciencesPubMed
Innovation Fund for Medical Sciences (CIFMS)PubMed
Gusu Innovation and Entrepreneurship Talent ProgramPubMed
Basic Research Program of JiangsuPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in40,729,309Unveiling cancer crosstalk: Mapping complexity across time and space.https://conductscience.org/library/papers/40729309

Source PubMed

References192

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,272,364Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development.Nat Commun2021https://conductscience.org/library/papers/34272364PubMed
229,311,381Metabolic Barriers to T Cell Function in Tumors.J Immunol2018https://conductscience.org/library/papers/29311381PubMed
333,546,704The cancer metabolic reprogramming and immune response.Mol Cancer2021https://conductscience.org/library/papers/33546704PubMed
438,367,240Suppression of the METTL3-m6A-integrin β1 axis by extracellular acidification impairs T cell infiltration and antitumor activity.Cell Rep2024https://conductscience.org/library/papers/38367240PubMed
535,181,605D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.Proc Natl Acad Sci U S A2022https://conductscience.org/library/papers/35181605PubMed
635,316,657The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming.Cell Metab2022https://conductscience.org/library/papers/35316657PubMed
731,730,395The Acidic Tumor Microenvironment as a Driver of Cancer.Annu Rev Physiol2020https://conductscience.org/library/papers/31730395PubMed
833,320,840Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer.J Clin Invest2021https://conductscience.org/library/papers/33320840PubMed
926,321,679Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.Cell2015https://conductscience.org/library/papers/26321679PubMed
1038,537,635Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells.Cell Metab2024https://conductscience.org/library/papers/38537635PubMed

1 to 10 of 192

See all 192 references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42,799,209Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.Int J Nanomedicine2026https://conductscience.org/library/papers/42799209PubMed
42,729,867Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Front Oncol2026https://conductscience.org/library/papers/42729867PubMed
42,711,333Disulfidptosis: molecular mechanisms and therapeutic targets.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42711333PubMed
42,694,706Exercise and antitumor immunity: molecular signaling, immune dynamics, and remodeling of the tumor microenvironment.Front Immunol2026https://conductscience.org/library/papers/42694706PubMed
42,676,625Mitochondrial transfer: a new perspective on tumor-microenvironment crosstalk driving metastasis.Front Immunol2026https://conductscience.org/library/papers/42676625PubMed
42,550,459PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.Radiol Med2026https://conductscience.org/library/papers/42550459PubMed
42,522,137Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics.Cancer Biol Ther2026https://conductscience.org/library/papers/42522137PubMed
42,518,007Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination.Inflammopharmacology2026https://conductscience.org/library/papers/42518007PubMed
42,509,750Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression.Biomolecules2026https://conductscience.org/library/papers/42509750PubMed
42,421,916Editorial: Empowering cancer care through immunonutrition.Front Nutr2026https://conductscience.org/library/papers/42421916PubMed

1 to 10 of 20

See all 20 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40658684

GET https://conductscience.org/api/papers/v1/40658684/references?page=2

API referenceFor AI assistants